stockrow
Saturday 7 November 2026
Export POM’s income statement to Excel — free account
Pomdoctor Limited - Sponsored ADR
POM Healthcare Pharmaceutical Retailers
Pomdoctor Limited - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $57.2 million, up 21.9% from fiscal 2024.
1.81
0.42
+30.22%
Follow POM
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 47 | 57 | — | +21.9% | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | 13.92 | 13.07 | — | (0.8) pt | ||||||
| EBT | — | — | — | — | — | — | — | — | (5) | (19) | — | +265.8% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | (10.91) | (32.74) | — | (21.8) pt | ||||||
| Net income | — | — | — | — | — | — | — | — | (5) | (19) | — | +265.8% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 74.45 | 59.13 | — | (20.6%) | |||||
| Earnings | — | — | — | — | — | — | — | — | (8.12) | (31.23) | — | +284.6% | ||||||
| Cash flow | — | — | — | — | — | — | — | — | (3.51) | (21.95) | — | +526.3% | ||||||
| Capex | — | — | — | — | — | — | — | — | (0.01) | (0.15) | — | +1,941.1% | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (3.51) | (22.10) | — | +529.2% | ||||||
| Book value | — | — | — | — | — | — | — | — | (491.89) | (71.17) | 0.00 | (85.5%) | ||||||
| Shares, m | — | — | — | — | — | — | — | — | 1 | 1 | — | +53.4% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (2) | (21) | — | +860.8% | |||||
| Capex | — | — | — | — | — | — | — | — | 0 | 0 | — | +3,032.6% | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (2) | (21) | — | +865.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | (19) | (16) | (20) | (16.6%) | |||||
| Net debt | — | — | — | — | — | — | — | — | 59 | 63 | 64 | +7.3% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | (310) | (69) | (75) | (77.8%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (279.99) | — | (280.0) pt | |||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | 16.05 | — | +16.1 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 156 | 165 | — | +5.8% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.30 | 0.35 | — | +15.2% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · fundamentals updated 2 Nov 2026
Pomdoctor Limited - Sponsored ADR vs peers in Pharmaceutical Retailers (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| HITI High Tide Inc. | $234.4M | — (loss-making) | 23.4× | +30.72% (above 0%: growing) | +800.00% (above 0%: growing) | −7.91% (below 0%: shrinking) | 26.53% | 4.38% | Compare |
| PETS PetMed Express, Inc. | $26.9M | — (loss-making) | — (loss-making) | −19.86% (below 0%: shrinking) | n/m | +38.60% (above 0%: growing) | 27.63% | (15.19%) | Compare |
| POM Pomdoctor Limited - Sponsored ADR | $11.6M | — | — | — | — | — | — | — | |
| SCNX Scienture Holdings, Inc. | $5.1M | — (loss-making) | — (loss-making) | +3,235.92% (above 0%: growing) | n/m | −53.98% (below 0%: shrinking) | 97.73% | (785.71%) | Compare |
| RDGT Ridgetech Inc. | $2.7M | — (loss-making) | — (loss-making) | +113.14% (above 0%: growing) | n/m | +4,848.31% (above 0%: growing) | 22.81% | 0.00% | Compare |
| Median of peers | $16.0M | — | — | +71.93% | — | +15.35% | 27.08% | (7.59%) |